Transaction details
On April 16, 2026, John Brendan Doyle, the chief financial officer of Cognition Therapeutics Inc. (NASDAQ: CGTX), acquired 10,000 shares of the company’s common stock at $1.13 per share, for a total outlay of $11,299. Following the purchase, Mr. Doyle directly owns 627,509 shares of Cognition Therapeutics common stock.
Market moves and valuation signals
The purchase occurred as the company’s shares posted a notable run: a 22% gain over the prior week and a 220% increase over the last 12 months. According to InvestingPro analysis cited with the company’s data, CGTX appears undervalued relative to analyst targets, which range from $3 to $4 per share. That range indicates potential upside from the price level at which the CFO bought the stock. The same research offering includes a Pro Research Report covering CGTX alongside more than 1,400 U.S. equities.
Operational results and clinical progress
In recent corporate disclosures, Cognition Therapeutics reported fourth-quarter 2025 results and provided a full-year update showing a material narrowing of net losses. The company recorded a net loss of $23.5 million for the year, representing a 30.9% improvement compared with the prior year. Management attributed the change to efforts to streamline operations and improve efficiency.
Cognition Therapeutics also confirmed plans to advance its drug candidate zervimesine for the treatment of psychosis in dementia with Lewy bodies. The decision to pursue a registrational pathway follows encouraging findings from the Phase 2 SHIMMER trial, which evaluated neuropsychiatric inventory measurements in patients with mild-to-moderate DLB. As part of that progression, the company intends to meet with the U.S. Food and Drug Administration’s Division of Psychiatry in the second quarter of 2026 to discuss a registrational plan for DLB psychosis.
What this means in context
The CFO’s direct purchase increases his stake at a time when the stock has been volatile but trending strongly higher year-over-year. The company’s financials show reduced losses, and its clinical program is moving toward regulatory discussion. Investors and market participants may read the insider purchase alongside the clinical and financial updates when assessing risk and opportunity in the equity.
Limitations
The article reports the transaction, recent stock performance, analyst target ranges, the company’s reported net loss and improvement, and the company’s stated regulatory plans as provided in the company’s disclosures. It does not project outcomes or speculate on the FDA discussion or commercial prospects beyond the information presented by the company and the cited analysis.